---
title: "Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292201167.md"
description: "A groundbreaking dual CAR T cell therapy, which targets both CD19 and CD38 proteins, has progressed to Phase 1/2 clinical trials. This innovative approach aims to effectively treat complex autoimmune disorders affecting multiple body systems. The therapy's advancement indicates promising potential for addressing such conditions."
datetime: "2026-07-09T12:31:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292201167.md)
  - [en](https://longbridge.com/en/news/292201167.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292201167.md)
---

# Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

A groundbreaking dual CAR T cell therapy, which targets both CD19 and CD38 proteins, has progressed to Phase 1/2 clinical trials. This innovative approach aims to effectively treat complex autoimmune disorders affecting multiple body systems. The therapy's advancement indicates promising potential for addressing such conditions.

### Related Stocks

- [FATE.US](https://longbridge.com/en/quote/FATE.US.md)

## Related News & Research

- [Fate Therapeutics wins FDA IND clearance for dual-target CAR-T candidate FT839](https://longbridge.com/en/news/292199195.md)
- [Fate Therapeutics reports preliminary FT819 CAR-T data showing skin score improvement in systemic sclerosis patients](https://longbridge.com/en/news/291803727.md)
- [Fate Therapeutics Insiders Benefit From Selling Stock At US$1.54](https://longbridge.com/en/news/291826508.md)
- [Fate Therapeutics Q4 Earnings Summary & Key Takeaways](https://longbridge.com/en/news/277057214.md)
- [Fate Therapeutics updates corporate presentation; highlights FT819 Phase 1/2 progress, FT836 enrollment, $174.8M cash](https://longbridge.com/en/news/288772187.md)